Subclinical thyroid dysfunctions are independent risk factors for mortality in a 7.5-year follow-up: the Japanese–Brazilian thyroid study

José A Sgarbi1,2, Luiza K Matsumura1, Teresa S Kasamatsu1, Sandra R Ferreira1,3 and Rui M B Maciel1

1Division of Endocrinology, Laboratory of Molecular Endocrinology, Department of Medicine, Escola Paulista de Medicina, Federal University of São Paulo, Rua Pedro de Toledo 669, 11o. andar, 04029-032 São Paulo, SP, Brazil, 2Division of Endocrinology, Department of Medicine, Faculdade de Medicina de Marília, Marília, Brazil and 3Department of Nutrition, School of Public Health, University of São Paulo, São Paulo, Brazil

(Correspondence should be addressed to R M B Maciel; Email: rui.maciel@unifesp.br)

Abstract

Objective: The currently available data concerning the influence of subclinical thyroid disease (STD) on morbidity and mortality are conflicting. Our objective was to investigate the relationships between STD and cardiometabolic profile and cardiovascular disease at baseline, as well as with all-cause and cardiovascular mortality in a 7.5-year follow-up.

Design: Prospective, observational study.

Methods: An overall of 1110 Japanese–Brazilians aged above 30 years, free of thyroid disease, and not taking thyroid medication at baseline were studied. In a cross-sectional analysis, we investigated the prevalence of STD and its relationship with cardiometabolic profile and cardiovascular disease. All-cause and cardiovascular mortality rates were assessed for participants followed for up to 7.5 years. Association between STD and mortality was drawn using multivariate analysis, adjusting for potential confounders.

Results: A total of 913 (82.3%) participants had euthyroidism, 99 (8.7%) had subclinical hypothyroidism, and 69 (6.2%) had subclinical hyperthyroidism. At baseline, no association was found between STD and cardiometabolic profile or cardiovascular disease. Multivariate-adjusted hazard ratios (HRs (95% confidence interval)) for all-cause mortality were significantly higher for individuals with both subclinical hyperthyroidism (HR, 3.0 (1.5–5.9); n = 14) and subclinical hypothyroidism (HR, 2.3 (1.2–4.4); n = 13) than for euthyroid subjects. Cardiovascular mortality was significantly associated with subclinical hyperthyroidism (HR, 3.3 (1.4–7.5); n = 8), but not with subclinical hypothyroidism (HR, 1.6 (0.6–4.2); n = 5).

Conclusion: In the Japanese–Brazilian population, subclinical hyperthyroidism is an independent risk factor for all-cause and cardiovascular mortality, while subclinical hypothyroidism is associated with all-cause mortality.

Introduction

Subclinical thyroid disease (STD) is characterized by abnormal serum thyrotoxin (TSH) levels in the presence of free thyroxine (FT4) and total or free triiodothyronine (FT3) within their reference ranges (1–3). Epidemiological studies have reported a considerable prevalence of unsuspected STD in the general population (4–6), and clinicians have more frequently diagnosed this condition in their daily clinical practice. The main question that a clinician faces is whether a patient with STD requires treatment or whether an observational strategy could be safely followed (7); however, opinions diverge regarding the clinical significance of STD (8). Both subclinical hypothyroidism (SChypo) (9–15) and subclinical hyperthyroidism (SChyper) (16–20) have been associated with cardiovascular abnormalities; but there are no prospectively validated trials, and treatment remains nonevidence based (21–22).

One frequently raised question concerns the impact of STD on life expectancy, but findings emerging from epidemiological studies are very controversial on this matter (23–29).

In this study, we estimated the prevalence of STD in an entire Japanese–Brazilian population and assessed its associations with cardiometabolic profile and cardiovascular disease in individuals with unrecognized thyroid dysfunction. We also investigated the relationship between STD at baseline and all-cause and cardiovascular mortality in a 7.5-year follow-up.
Methods

Study population and design

A survey was conducted in a nonmixed Japanese–Brazilian population living in Bauru (Human Development Index 0.825; Source: www.ipeadata.gov.br), State of São Paulo, Brazil, which aimed to estimate the prevalence of diabetes and associated diseases in this community. A detailed description of this survey was reported previously (30). In summary, the entire population of ≥30 years of age (n = 1751) was invited, and 1330 (76%) individuals agreed to participate (Fig. 1). Reasons for nonparticipation (421 individuals, 24.0%) were refusal (64.6%), change of address (13.5%), and death (21.9%).

In the cross-sectional phase conducted in 1999–2000, the prevalence of thyroid dysfunction and the associations of STD with cardiometabolic profile or cardiovascular disease were assessed. Individuals were followed from 1999 to 2007 in order to investigate the influence of STD on all-cause and cardiovascular mortality.

Study procedures

Socio-demographic, cultural, lifestyle, and health data were obtained by standardized questionnaires and trained interviewers. A specific thyroid questionnaire that included family and personal history of thyroid disease was applied by experts in thyroid diseases.

Body weight and height were measured while individuals were wearing light clothing without shoes. Waist circumference was measured at the level of the umbilicus while standing and during slight expiration. Blood pressure was taken three times with an automatic device (Omron model HEM-712C, Omron Health Care, Bannockburn, IL, USA). The mean of the last two measurements was used to express systolic and diastolic blood pressure values. A standard 12-lead electrocardiogram (ECG) was obtained in the resting state by the standard procedure and was analyzed by two cardiologists. A Doppler probe (Imbracios 8 MHz) was used to determine the ankle–brachial pressure index for both extremities.

Fasting blood samples were taken and a 75-g oral glucose tolerance test was performed. Samples were processed for immediate analyses in the local laboratory or were stored at −80°C. Plasma glucose was measured by the glucose oxidase method, while the total cholesterol, high-density lipoprotein cholesterol (HDL-c), and triglycerides were enzymatically evaluated with an automatic analyzer. Low-density lipoprotein cholesterol (LDL-c) was calculated according to the Friedewald equation (31). Insulin concentration was determined by a MAB-based immunofluorometric assay (AutoDelphia, PerkinElmer Life Sciences Inc., Norton, OH, USA). Insulin resistance was calculated by the homeostasis model assessment (HOMA-IR = fasting insulin (mU/ml)/22.5 × fasting glycemia (mmol/l)).

Urinary iodine concentration (UIC) was measured in early-morning urine samples by a colorimetric method (32), with a detection limit of 10 µg/l and the normal range between 100 and 299 µg/l.

TSH levels were measured in duplicate by a sensitive immunofluorometric assay (Wallac–Delfia, PerkinElmer, Turku, Finland) with a reference range of 0.45–4.5 mU/l and functional sensitivity of 0.05 mU/l. Serum FT4 was measured using a competitive immunoassay (Wallac–Delfia), wherein the normal reference range was 0.7–1.5 ng/dl.

Date and cause of death were collected from death certificates between the start of the screening (November 1999) and June 2007. For individuals (n = 3) who moved out of the study area and for whom we were not able to have access to the death certificate, we asked families about the occurrence of death and its date and cause. In June 2007, the ascertainment of mortality was 100%. Cardiovascular death was defined as death from any cardiovascular or cerebrovascular event. All-cause mortality was defined as all deaths from any natural cause.

This study was approved by the ethics committee of Escola Paulista de Medicina, Federal University of São Paulo, and written informed consent was obtained from all participants.
**Definitions**

Euthyroidism was defined as serum TSH and FT₄ within the normal reference ranges: SChyper as TSH below 0.45 mU/l with normal FT₄ level; overt hyperthyroidism as TSH below 0.1 mU/l with high FT₄ level; SChypo as TSH above 4.5 mU/l with normal FT₄ level; and overt hypothyroidism as TSH above 4.5 mU/l with low FT₄ level or a TSH concentration above 20 mU/l (21).

Hypertension was defined as a blood pressure ≥140/90 mmHg or as the use of antihypertensive medication; diabetes was defined according to the American Diabetes Association criteria; and dyslipidemia was defined by the presence of any lipid abnormality (total cholesterol levels ≥200 mg/dl or triglycerides ≥150 mg/dl or LDL-c > 130 mg/dl).

The presence of cardiovascular disease at baseline was defined by a medical history of myocardial infarction confirmed by a physician and by major ECG abnormalities of old infarction (Q waves) or by previous angioplasty or any heart revascularization procedure, or coronary insufficiency diagnosed previously by catheterization, or stroke. Peripheral arterial disease was defined by any ankle–brachial pressure index < 0.9 (33).

**Statistical analysis**

Prevalence rates were calculated by point and confidence interval (CI). The data were described through absolute (n) or relative (%) frequencies, mean with s.d., and 95% CI. Differences in means of the baseline characteristics according to thyroid status categories were assessed by ANOVA (Tukey’s test for multiple comparisons if P < 0.05) or nonparametric ANOVA (Kruskal–Wallis test), followed by the Mann–Whitney U test. Frequencies were compared by the χ² test or the Fisher test when one of the absolute frequencies was below five. Variables without a normal distribution were subjected to logarithmic transformations before statistical analysis.

In the longitudinal analysis, survival curves according to thyroid status across the 7.5 years of follow-up were estimated using Kaplan–Meier analysis with the log-rank test. They were constructed considering the death as ‘event’ and contrary cases as ‘not event’ (censorship), which were predicted by the baseline thyroid status. Living individuals who did not complete the 7.5 years of follow-up by June 30, 2007 were censored for survival at 7.5 years. A Cox regression model of proportional risks in bivariate analysis was used to determine the crude hazard ratios (HRs). Multivariate analysis was used to account for potential confounders of the mortality rate. Relevant confounders were selected by their significant association with mortality (age, sex, presence of hypertension, diabetes mellitus, and cardiovascular disease), which were determined by the χ² test or the Fisher test when frequencies were compared, and by the Student t-test or the Mann–Whitney test (for variables without normal distribution). Risk factors classically associated with mortality were also considered (total cholesterol, smoking status, and waist circumference), totalling a maximum of eight risk factors (maximum of one risk factor for every ten deaths). In cases of variables with co-linear inter-relationships, such as diabetes and fasting or 2-h plasma glucose levels, hypertension and systolic blood pressure, and total cholesterol and LDL-c, only one was considered. Models were first adjusted for age and sex, and afterwards for the relevant confounders. A Cox regression model of proportional risks in bivariate analysis was used to determine multiple HRs with 95% CI to express the adjusted relative risk of dying for individuals classified as having STD relative to euthyroid individuals. All statistical analyses were performed using SAS statistical software version 9.1 (SAS Institute Inc., Cary, NC, USA). The assumed level of significance was at P < 0.05 (two-tailed).

**Results**

From the 1330 individuals who agreed to participate in this cohort, we excluded those who self-reported thyroid disease or taking thyroid medications (n = 47), and those who reported to be using amiodarone, lithium, or corticosteroids (n = 6). Furthermore, we excluded 167 participants for whom ECG and ankle–brachial pressure indices were not available. Thus, 1110 individuals were considered for the present analysis (Fig. 1). There was no difference in demographic characteristics between included (n = 1110) and excluded (n = 220) individuals.

**Cross-sectional analysis**

Prevalence rates for each thyroid status category are presented in Table 1. The median UIC was 210 μg/L, with no statistical difference among the thyroid status categories (Table 2). Euthyroidism, overt, and SChyper

---

**Table 1** Demographic characteristics and thyroid status in Japanese–Brazilians.

<table>
<thead>
<tr>
<th>Demographic characteristics</th>
<th>Total participants (n)</th>
<th>Women, n (%)</th>
<th>Mean age, years (s.d.)</th>
<th>Age distribution, n (%)</th>
<th>Thyroid status, prevalence rates, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total participants (n)</td>
<td>1110</td>
<td>591 (53.2)</td>
<td>56.9 (12.5)</td>
<td>30–39 years</td>
<td>96 (65.3)</td>
</tr>
<tr>
<td>Women, n (%)</td>
<td>591 (53.2)</td>
<td>324 (77.0)</td>
<td>57.6 (12.2)</td>
<td>40–49 years</td>
<td>229 (60.6)</td>
</tr>
<tr>
<td>Mean age, years (s.d.)</td>
<td>56.9 (12.5)</td>
<td>56.9 (12.5)</td>
<td>56.9 (12.5)</td>
<td>50–59 years</td>
<td>311 (28.3)</td>
</tr>
<tr>
<td>Age distribution, n (%)</td>
<td>30–39 years</td>
<td>229 (20.6)</td>
<td>50–59 years</td>
<td>60–69 years</td>
<td>285 (25.7)</td>
</tr>
<tr>
<td></td>
<td>40–49 years</td>
<td>229 (20.6)</td>
<td>&gt;70 years</td>
<td></td>
<td>189 (17.0)</td>
</tr>
<tr>
<td>Thyroid status, prevalence rates, % (95% CI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>82.3 (80.8–84.9)</td>
</tr>
<tr>
<td>Euthyroidism, n = 913</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.8 (1.0–2.6)</td>
</tr>
<tr>
<td>Overt hyperthyroidism, n = 20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.2 (4.7–7.5)</td>
</tr>
<tr>
<td>Subclinical hyperthyroidism, n = 69</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.8 (0.3–1.3)</td>
</tr>
<tr>
<td>Overt hypothyroidism, n = 9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8.9 (7.0–10.1)</td>
</tr>
<tr>
<td>Subclinical hypothyroidism, n = 99</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval.
Table 2  Baseline characteristics according to thyroid status. Data are presented as mean±s.d., unless noted otherwise.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Euthyroid (n=913)</th>
<th>Overt hyperthyroid (n=20)</th>
<th>Subclinical hyperthyroid (n=69)</th>
<th>Overt hypothyroid (n=9)</th>
<th>Subclinical hypothyroid (n=99)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women, n (%)</td>
<td>469 (51.4)</td>
<td>10 (50.0)</td>
<td>42 (60.9)</td>
<td>7 (77.8)*</td>
<td>63 (63.6)*</td>
</tr>
<tr>
<td>Men, n (%)</td>
<td>444 (48.6)</td>
<td>10 (50.0)</td>
<td>27 (39.1)</td>
<td>2 (22.2)</td>
<td>36 (36.4)</td>
</tr>
<tr>
<td>Mean age, years (s.d.)</td>
<td>56.4 (12.4)</td>
<td>56 (12.2)</td>
<td>61.4 (12.5)†</td>
<td>65.1 (13.4)</td>
<td>58.5 (12.3)</td>
</tr>
</tbody>
</table>

Age distribution, n (%)

- 30–39 years: 79 (8.7) vs. 2 (10.0) vs. 5 (7.2) vs. – vs. 2 (10.0)
- 40–49 years: 205 (22.5) vs. 4 (20.0) vs. 8 (11.6) vs. 1 (11.1) vs. 11 (11.1)
- 50–59 years: 259 (28.4) vs. 5 (25.0) vs. 13 (18.8) vs. 2 (22.2) vs. 32 (32.3)
- ≥ 60 years: 224 (24.5) vs. 7 (35.0) vs. 24 (34.8) vs. 3 (33.3) vs. 27 (27.3)

Characteristics

- BMI (kg/m²): 25.1 (3.9) vs. 24.1 (2.6) vs. 24.5 (4.2) vs. 23.6 (2.0) vs. 24.5 (3.7)
- Waist circumference (cm): 84.5 (10.6) vs. 83.2 (8.8) vs. 83.9 (9.9) vs. 78.6 (4.9) vs. 82.5 (9.8)
- Current smoker, n (%): 120 (13.2) vs. 2 (10.0) vs. 5 (7.2) vs. – vs. 10 (10.1)
- Past smoker, n (%): 173 (19.1) vs. 9 (45.0)* vs. 12 (17.4) vs. 2 (22.2) vs. 12 (12.1)
- Hypertension, n (%): 342 (38.5) vs. 6 (30.0) vs. 32 (46.4) vs. 4 (44.4) vs. 4 (44.4)
- Diabetes, n (%): 328 (36.9) vs. 11 (55.0) vs. 30 (43.5) vs. 2 (22.2) vs. 35 (35.4)
- PAD, n (%): 117 (12.8) vs. 3 (15.0) vs. 14 (19.3) vs. 2 (22.2) vs. 10 (10.1)
- CVD, n (%): 120 (13.1) vs. 5 (25.0) vs. 13 (18.8) vs. 3 (33.3) vs. 15 (15.2)
- Statin usage, n (%): 13 (1.4) vs. 1 (1.4) vs. 1 (1.4) vs. 1 (11.1)* vs. 5 (5.1)*
- Systolic BP (mmHg): 132.8±24.4 vs. 127.5±18.7 vs. 135.5±26.3 vs. 130.1±32.4 vs. 133.5±25.2
- Diastolic BP (mmHg): 79.3±13.3 vs. 72.4±12.8 vs. 78.8±12.8 vs. 76.2±11.4 vs. 78.2±14.2
- UIC (µg/l): 204±103 vs. 184±99 vs. 207±113 vs. 235±68 vs. 221±113
- TSH (mU/l): 1.62±0.94 vs. 0.1±0.11§ vs. 0.22±0.1§ vs. 0.74±0.1§ vs. 7.1±2.8§
- Free T4 (µg/dl): 1.07±0.17 vs. 3.2±2.7§ vs. 1.12±0.18§ vs. 0.53±0.22§ vs. 1.01±0.2§
- Fasting glucose (mg/dl): 124.4±33.5 vs. 137.0±57.6 vs. 127.9±40.1 vs. 113.2±8.3 vs. 122.6±29.8
- Two-hour glucose (mg/dl): 166.5±76.9 vs. 184.3±98.8 vs. 184.4±87.2 vs. 135.1±42.4 vs. 161.6±87.9
- Fasting insulin (pmol/l): 63.2±49.5 vs. 48.8±32.3 vs. 66.0±46.7 vs. 82.6±117.7 vs. 63.9±55.3
- HOMA-IR*: 2.8±2.6 vs. 2.9±2.1 vs. 3.0±2.7 vs. 3.2±2.7 vs. 2.8±2.6
- Total cholesterol (mg/dl): 215.0±41.1 vs. 193.2±53.7† vs. 207.4±31.7 vs. 240.8±49.9* vs. 214.4±47.6
- LDL-c (mg/dl): 131.2±37.3 vs. 119.6±44.9 vs. 125.9±31.9 vs. 158.1±40.4* vs. 126.0±43.7
- HDL-c (mg/dl): 50.8±10.9 vs. 46.8±9.5 vs. 48.9±7.2 vs. 55.9±10.5 vs. 50.6±12.9
- Triglycerides (mg/dl): 232.3±189.5 vs. 224.4±177.1 vs. 209.0±118.5 vs. 172.8±112.9 vs. 250.7±197.9

BMI, body mass index; PAD, peripheral arterial disease; CVD, cardiovascular disease; BP, blood pressure; UIC, urinary iodine concentration; TSH, thyrotropin; HOMA-IR, homeostasis model assessment for insulin resistance; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol. *P<0.05; †P<0.01; §P<0.001; ‡P<0.0001. Values were log-transformed for statistical analysis.

were found in 82.3, 1.8, and 6.2% of the participants respectively, with no significant difference in sex distribution (Table 2). On the other hand, unsuspected overt and SCypo were identified in 0.8 and 8.9% of the participants respectively, both significantly more frequent in women (P=0.04). The mean age was similar among the groups, except for the SCyper group, in which age was significantly higher relative to the euthyroid group. As noted in Table 2, the expected significant increases in TSH and FT4 levels were observed between euthyroid individuals and those with STD.

There were no statistically significant differences among the groups concerning body mass index, waist circumference, smoking status, systolic or diastolic blood pressure, fasting or 2-h plasma glucose, fasting serum insulin, HOMA-IR, HDL-c, or triglyceride levels (Table 2). Mean total cholesterol (P=0.03) and LDL-c (P=0.02) levels were significantly increased in overt hypothyroid subjects, but not in SCypo subjects in comparison to euthyroid individuals. However, the proportion of individuals undergoing statin therapy was significantly higher in both overt hypothyroid and SCypo groups than in the euthyroid group (P<0.05). The OR for statin use, adjusted for age and sex, was significantly higher in SCypo individuals (3.4 (95% CI, 1.2–9.8)) than in the euthyroid individuals. Since statin use could be masking a potential association between serum levels of lipids and SCypo, the analysis was repeated excluding this condition, but the results did not change.

The overall proportions of diabetes, hypertension, peripheral arterial disease, and cardiovascular disease were not statistically different among the groups (Table 2).

**Longitudinal analysis**

During the 7.5 years of follow-up, 83 (7.5%) deaths were recorded in this population. Four events of death by nonnatural causes (one by suicide and three by trauma) were censored, and three deaths by unknown causes were censored just for the cardiovascular death analyses. The deaths by unknown causes occurred in
the euthyroid \((n=2)\) and in the SChyper \((n=1)\) group. Deaths mainly occurred as a result of cardiovascular causes \((51.3\%)\), cancer \((22.3\%)\), or infectious disease \((14.5\%)\). Table 3 shows the main differences between living and dead individuals. Among the dead subjects, 50 \((65.8\%)\) had been categorized as euthyroid, 14 \((17.7\%)\) as SChyper, and 13 \((16.5\%)\) as SChypo. No death was notified among individuals who were classified as having overt thyroid disease. At baseline, serum FT\(_4\) levels were significantly higher \((P<0.018)\) among dead individuals than among those who were alive at the end of the follow-up, but no differences in TSH levels were found between the groups.

Table 4 shows the relationship between STD and mortality. All-cause mortality was significantly higher in SChyper \((20.3\%)\) and SChypo \((13.1\%)\) individuals than in euthyroid \((5.7\%)\) individuals \((P<0.0001)\). Kaplan–Meier analysis (Fig. 2) with the log-rank test reveals higher overall mortality for both SChyper \((P<0.0001)\) and SChypo \((P=0.0035)\) groups in comparison to the euthyroid group. Cardiovascular mortality was significantly associated with SChyper \((P<0.0001)\). These differences emerged after 4 years of the follow-up. Cox regression analysis (Table 4) revealed that these significant associations were preserved even after adjusting for age, sex, and multiple potential confounders.

**Discussion**

In this study, we found a strong relationship between SChyper and all-cause and cardiovascular mortality, while SChypo was significantly associated with all-cause mortality. These significant associations with mortality emerged after 4 years of follow-up.

**Table 3** Thyroid status, demographic characteristics, and biological variables according to vital status at the end of the follow-up. Data are presented as mean \(\pm\) s.d., unless noted otherwise.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Alive ((n=1031))</th>
<th>Dead ((n=79))</th>
<th>(P) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Euthyroidism</td>
<td>861 (83.5)</td>
<td>52 (65.8)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Overt hyperthyroidism</td>
<td>20 (1.9)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>SChyper</td>
<td>55 (5.3)</td>
<td>14 (17.7)</td>
<td></td>
</tr>
<tr>
<td>Overt hypothyroidism</td>
<td>9 (0.9)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>SChypo</td>
<td>86 (8.3)</td>
<td>13 (16.5)</td>
<td></td>
</tr>
<tr>
<td>Men, (n) (%)</td>
<td>472 (45.8)</td>
<td>47 (59.5)</td>
<td>0.02</td>
</tr>
<tr>
<td>Women, (n) (%)</td>
<td>559 (54.2)</td>
<td>32 (40.5)</td>
<td></td>
</tr>
<tr>
<td>Mean age, years</td>
<td>56.1 (\pm) 12.2</td>
<td>67.7 (\pm) 11.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Distribution of age, (n) (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30–39 years</td>
<td>95 (9.2)</td>
<td>1 (1.3)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>40–49 years</td>
<td>225 (21.8)</td>
<td>4 (5.1)</td>
<td></td>
</tr>
<tr>
<td>50–59 years</td>
<td>297 (28.8)</td>
<td>14 (17.7)</td>
<td></td>
</tr>
<tr>
<td>60–69 years</td>
<td>264 (25.6)</td>
<td>21 (26.6)</td>
<td></td>
</tr>
<tr>
<td>≥ 70 years</td>
<td>150 (14.5)</td>
<td>39 (49.4)</td>
<td></td>
</tr>
<tr>
<td>Survival time, years</td>
<td>7.3 (\pm) 0.3</td>
<td>4.1 (\pm) 2.0</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>BMI(^a) (kg/m(^2))</td>
<td>25.1 (\pm) 3.8</td>
<td>24.1 (\pm) 4.3</td>
<td>0.03</td>
</tr>
<tr>
<td>Waist circumference(^a) (cm)</td>
<td>84.2 (\pm) 10.3</td>
<td>84.7 (\pm) 11.3</td>
<td>0.07</td>
</tr>
<tr>
<td>Current smoker, (n) (%)</td>
<td>125 (12.2)</td>
<td>12 (15.2)</td>
<td>0.72</td>
</tr>
<tr>
<td>Past smoker, (n) (%)</td>
<td>193 (18.8)</td>
<td>15 (19.0)</td>
<td></td>
</tr>
<tr>
<td>Hypertension, (n) (%)</td>
<td>379 (36.8)</td>
<td>48 (60.8)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Diabetes, (n) (%)</td>
<td>366 (35.5)</td>
<td>40 (50.6)</td>
<td>0.007</td>
</tr>
<tr>
<td>PAD, (n) (%)</td>
<td>129 (12.5)</td>
<td>13 (16.5)</td>
<td>0.31</td>
</tr>
<tr>
<td>CVD, (%)</td>
<td>133 (12.9)</td>
<td>23 (29.1)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Statin usage, (n) (%)</td>
<td>19 (1.8)</td>
<td>1 (1.3)</td>
<td>1.0</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>132.0 (\pm) 24.0</td>
<td>145.3 (\pm) 27.4</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>79.0 (\pm) 13.3</td>
<td>80.6 (\pm) 14.2</td>
<td>0.47</td>
</tr>
<tr>
<td>UIC ((\mu g/dl))</td>
<td>20.7 (\pm) 10.5</td>
<td>19.7 (\pm) 9.0</td>
<td>0.56</td>
</tr>
<tr>
<td>TSH (mU/l)</td>
<td>2.5 (\pm) 9.2</td>
<td>2.4 (\pm) 2.8</td>
<td>0.86</td>
</tr>
<tr>
<td>Free (T_4) (ng/dl)</td>
<td>1.1 (\pm) 0.5</td>
<td>1.13 (\pm) 0.22</td>
<td>0.018</td>
</tr>
<tr>
<td>Fasting glucose (mg/dl)</td>
<td>124.3 (\pm) 33.9</td>
<td>127.1 (\pm) 36.9</td>
<td>0.63</td>
</tr>
<tr>
<td>Two-hour glucose (mg/dl)</td>
<td>165.5 (\pm) 78.2</td>
<td>189.3 (\pm) 85.1</td>
<td>0.006</td>
</tr>
<tr>
<td>Fasting insulin (pmol/l)</td>
<td>61.7 (\pm) 49.3</td>
<td>52.7 (\pm) 36.8</td>
<td>0.09</td>
</tr>
<tr>
<td>HOMA-IR(^a)</td>
<td>2.8 (\pm) 2.6</td>
<td>2.4 (\pm) 2.1</td>
<td>0.11</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>214.8 (\pm) 40.9</td>
<td>207.3 (\pm) 50.8</td>
<td>0.02</td>
</tr>
<tr>
<td>LDL-c (mg/dl)</td>
<td>130.9 (\pm) 37.9</td>
<td>124.3 (\pm) 36.6</td>
<td>0.1</td>
</tr>
<tr>
<td>HDL-c (mg/dl)</td>
<td>50.8 (\pm) 10.9</td>
<td>48.2 (\pm) 10.1</td>
<td>0.04</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>233.7 (\pm) 189.8</td>
<td>208.1 (\pm) 109.7</td>
<td>0.6</td>
</tr>
</tbody>
</table>

SChyper, subclinical hyperthyroidism; SChypo, subclinical hypothyroidism; BMI, body mass index; PAD, peripheral arterial disease; CVD, cardiovascular disease; BP, blood pressure; UIC, urinary iodine concentration; TSH, thyrotropin; HOMA-IR, homeostasis model assessment for insulin resistance; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol.

\(^a\)Values were log-transformed for statistical analysis.

www.eje-online.org
Despite differences in the population characteristics, these results are similar to those found by Parle et al. (23) and Gusseklo et al. (25), by having a significant association between mortality and SCHyper, and because increased levels of FT₄ were also associated with increased all-cause mortality. However, we could not confirm Gusseklo’s findings of lower mortality among octogenarians with increased TSH levels because our small number of individuals and events limited our power to detect significant associations in that age group. Such a strong association was also reported in a recent meta-analysis (34), in which SCHyper was associated with a significant increase in the relative likelihood of death from all causes, whereas another meta-analysis found only a modest association (35). On the other hand, our findings disagree with previous studies (28, 29), which found no association between SCHyper and mortality. These studies were larger and had a greater follow-up than the current cohort. Therefore, both had a lower prevalence of SCHyper, and in one (28), analysis of death was based on only three events, limiting the power to detect an effect of SCHyper on mortality.

In the present report, SCHypo was significantly associated with death in all cases, but not with cardiovascular mortality. However, as can be noted in Table 4, the point estimates for association between SCHypo and cardiovascular mortality ranged from 1.6 to 1.8 in the different models, but with very large CIs. The small number of cardiovascular deaths (five events) probably limited our ability to detect an association between SCHypo and cardiovascular mortality, and these HRs might have been significant with a larger number of outcomes.

These data partially agree with a Japanese study (24), although in such a study, the association between SCHypo and mortality disappeared by the 10-year mark. Despite our shorter follow-up, we do not have any evidence of a similar outcome in our population, as the association between STD and mortality became more pronounced throughout the study (Fig. 2). In addition, comparisons between these cohorts should be done with caution, given that they have been exposed to different iodine intake, and because such a study (24) was highly selective in that it only included survivors of the atomic bomb. Our findings also agree with two recent meta-analyses (34, 35), but differ from others (36, 37) and from recent observational studies (28, 29); however, in one of them (29) the mean age of the population (72.7 years) was higher than that of our population. This difference is of particular importance since it has been suggested (38) that SCHypo is associated with mortality in only relatively younger populations (≤ 65 years).

In this cohort, mortality was associated with some metabolic and clinical variables (Table 3); however, the causal role of STD for mortality remained significant, even after a multivariate analysis adjusted for all variables significantly related to mortality and for those classically known to have an association with mortality. Findings regarding the relationship between STD and mortality are very discrepant, mainly because confounders known to affect prognosis have not been carefully considered in many studies (37).

The prevalence rates for STD in this population confirm previous epidemiological studies reporting an elevated prevalence of unsuspected STD in the general population (4–6). The prevalence of SCHypo in this study was similar to that reported previously (4–6), while the rate of SCHyper was higher than that reported for iodine-sufficient Western (4–6, 29) and Japanese populations (39, 40). The reason for this difference is not clear; however, similar findings were found in another Brazilian population study (41). It has been reported that 5 years of excessive iodine intake (1998–2003) may have increased the prevalence of hyperthyroidism in Brazil (42), but only 17.5% of the Japanese–Brazilians had an increased UIC, and no difference in UIC was found among the thyroid categories. This population could be studied during a time when iodine supply was shifted from a mildly deficient to a sufficient or more than sufficient supply, but unfortunately no data for iodine status exist before the time of the study. There is a possibility of selection bias in having included

### Table 4 Hazard ratios (95% confidence interval (CI)) for 7.5-year mortality due to all and cardiovascular causes among 1110 Japanese–Brazilians.

<table>
<thead>
<tr>
<th></th>
<th>Euthyroidism (n=913)</th>
<th>Subclinical hyperthyroidism (n=69)</th>
<th>Subclinical hypothyroidism (n=99)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality, n (%)</td>
<td>52 (5.7)</td>
<td>14 (20.3)</td>
<td>13 (13.1)</td>
</tr>
<tr>
<td>Crude</td>
<td>1</td>
<td>4.0 (2.2–7.2)</td>
<td>2.2 (1.2–4.3)</td>
</tr>
<tr>
<td>Model 1</td>
<td>1</td>
<td>3.4 (1.9–6.3)</td>
<td>2.2 (1.2–4.1)</td>
</tr>
<tr>
<td>Model 2</td>
<td>1</td>
<td>3.0 (1.5–5.9)</td>
<td>2.3 (1.2–4.4)</td>
</tr>
<tr>
<td>Cardiovascular mortality, n (%)</td>
<td>26 (2.8)</td>
<td>6 (1.6)</td>
<td>5 (5.1)</td>
</tr>
<tr>
<td>Crude</td>
<td>1</td>
<td>4.5 (2.1–10.0)</td>
<td>1.8 (0.7–4.6)</td>
</tr>
<tr>
<td>Model 1</td>
<td>1</td>
<td>3.7 (1.6–8.4)</td>
<td>1.7 (0.6–4.3)</td>
</tr>
<tr>
<td>Model 2</td>
<td>1</td>
<td>3.3 (1.4–7.5)</td>
<td>1.6 (0.6–4.2)</td>
</tr>
</tbody>
</table>

CI, confidence interval. Data are given as hazard ratio (95% CI). Model 1, adjusted for age and sex. Model 2, adjusted for Model 1 plus hypertension, diabetes mellitus, cardiovascular disease, total cholesterol, smoking status, and waist circumference.
some individuals with nonthyroidal illness (43), but it is not very likely to be of significance in this study, since FT4 levels were significantly higher in individuals with SCHyper than in euthyroid subjects (Table 2), which is consistent with mild thyroid hormone excess. Finally, the use of slimming pills, a common practice in Brazil (44), could have affected the prevalence of SCHyper in our population, but participants did not report such use.

No consistent association of STD with cardiometabolic risk factors was found at baseline in this study (Table 2). These findings agree with some previous large population-based studies (4, 29, 45, 46), but differ from others (5, 6, 28). In two of these studies (6, 28), the difference disappeared after adjusting for other relevant risk factors, such as age, sex, and statin use. A meta-analysis (47) found a significant decrease in total serum cholesterol levels following l-T4 therapy; but most of the selected studies had a nonrandomized design. In contrast, a systematic review (48) found only marginal evidence indicating an association between thyroid hormone replacement and improvement in lipid profile.

We found no association of STD with cardiovascular disease or with peripheral arterial disease at baseline in this study, which is similar to some studies (28, 29, 50). A modest association of SCHypo with an increased risk of coronary heart disease at baseline and at follow-up has been found in different studies and meta-analyses (28, 35, 36, 45, 51), but the estimated risk was close to 1.0 when only higher quality studies were pooled (35). A recent analysis suggested that SCHypo may be associated with increased cardiovascular risk only in middle-aged (<65 years old) individuals (38). Unfortunately, the small number of events eliminates the ability to perform meaningful analysis according to age in the present study.

The major strength of our study lies in our inclusion of an entire population. In addition, participants were examined by thyroid experts, and individuals who self-reported thyroid diseases or were taking thyroid medications were excluded from the analysis; life status was obtained for all participants, and mortality risk was adjusted for multiple confounders.

This study also has several limitations, including the fact that our data are based only on a baseline set of thyroid tests. Thus, we cannot exclude the possibility of influence determined by the progression from subclinical to overt thyroid dysfunction on the risk of mortality; however, this limitation is common to all previously published studies. We also had a relatively small number of cardiovascular deaths, decreasing the power of the analysis and our ability to detect an association with SCHypo. Another limitation is the lack of analysis stratified according to age, sex, and TSH levels due to the small numbers of events. In addition, we are unable to exclude the possibility of overt thyrotoxicosis in some of our SCHyper individuals, since T3 and FT3 serum levels were not determined in this study. Furthermore, cause of death was only based on death certificates without additional validation by hospital records for those who died in the hospital. Finally, we cannot guarantee the generalizability of the findings due to our selected population of Japanese–Brazilians.
In summary, SCHyper is an independent risk factor for all-cause and cardiovascular mortality, whereas SCHypto is associated with increased all-cause mortality among Japanese–Brazilians. These findings suggest that further preventive strategies of treatment are necessary in order to reduce mortality associated with STD in the general population; however, to demonstrate some therapeutic benefit, large, well-designed, randomized, and placebo-controlled trials of STD treatment will be needed. Thus, while the treatment of STD persists as a non evidence-based program, the choice between treating and not treating patients with persistent endogenous STD remains dependent on the best clinical judgment.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
The Japanese–Brazilian thyroid study was supported by an unrestricted grant from the São Paulo State Research Foundation (Fundaçao de Amparo à Pesquisa do Estado de Sao Paulo, FAPESP, grant 06/59737-9 to Dr Maciel).

Acknowledgements
We are grateful to the Japanese–Brazilian population and to the Japanese–Brazilian Diabetes Study Group, particularly to Drs Amélia Hirai and Suei Gimenho. We gratefully acknowledge De Helena Villar for helping in the collection of clinical and thyroid data. We thank Sirlei Siani Morais for the statistical assistance. We are also grateful to Gilberto Furuzawa and Patricia Hiroya for technical assistance and to Angela Faria for administrative assistance. Dr Maciel is a researcher from the Brazilian Research Council (CNPq) and from the Fleury Institute.

References
21. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NE, Cobin RH, Franklin JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS & Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. Journal of the American Medical Association 2004 291 178–188.
22. Gharib H, Tuttle M, Baskin HJ, Fish LH, Singer PA & McDermott MT. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical
Subclinical thyroid dysfunction and mortality


Received 26 November 2009
Accepted 2 December 2009


www.eje-online.org